AURORA, Colo., Jan. 31, 2022 — Summit Biolabs, a commercial-stage molecular diagnostics company
harnessing the power of direct-to-PCR technology to transform the detection of infectious diseases, today announced they passed the next significant COVID-19 test processing milestone last week. In just a few months, they completed an additional 250,000 tests, bringing the total to over 500,000 COVID-19 tests processed from Summit’s CLIA-certified laboratory in Aurora, Colorado. These tests were performed using Summit Biolabs’ own commercial laboratory-developed, direct-to-PCR tests for COVID-19, SwabFASTTM and SalivaFASTTM.
Bob Blomquist, Chief Executive Officer of Summit Biolabs commented, “We are proud that our lab has been able dramatically expand capacity and continue to support the public health efforts to combat the latest wave of the COVID-19 pandemic. We applaud the diligent and hardworking laboratory technicians who have worked tirelessly to perform accurate and timely tests on such a high volume of samples.”
About Summit Biolabs
Summit Biolabs is a commercial-stage molecular diagnostics company harnessing the power of direct-to- PCR technology to transform the detection of infectious diseases like COVID-19, influenza A/B, and sexually transmitted infections.
Summit Biolabs was spun out of Dr. Shi-Long Lu’s laboratory at the University of Colorado Anschutz Medical Campus. The company leveraged its competencies in viral detection in saliva and direct-to-PCR platform technology to help combat the pandemic. Summit developed and deployed two highly accurate, robust, rapid, and high-throughput PCR tests for COVID-19 diagnosis. These commercial laboratory- developed tests eliminate the time and cost of nucleic acid extraction, while significantly improving the turn-around-time for results. During 2021, Summit Biolabs’ CLIA-certified laboratory performed over 410,000 tests for COVID-19, with over 88% of those tests performed since August 1. A rapid testing pathway for high-priority samples returns results in < 3 hours from receipt of samples.
Summit Biolabs has ongoing test development projects capitalizing on our direct-to-PCR platform technology for other indications. The company’s high-complexity, molecular diagnostics CLIA laboratory is located at Bioscience 3 on the Fitzsimons Innovation Campus in Aurora, Colorado.
